Optinose to Present at the Piper Sandler Virtual Healthcare Conference
23 nov. 2021 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 nov. 2021 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
18 nov. 2021 14h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
16 nov. 2021 08h02 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Proposed Public Offering of Common Stock
15 nov. 2021 17h40 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
15 nov. 2021 16h26 HE
|
Optinose, Inc.
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and...
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
10 nov. 2021 17h50 HE
|
Optinose, Inc.
Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
28 oct. 2021 06h59 HE
|
Optinose, Inc.
Company Expects Top-Line Results in Second Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose to Present at the Cantor Virtual Global Healthcare Conference
22 sept. 2021 16h15 HE
|
Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
11 août 2021 07h00 HE
|
Optinose, Inc.
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call...